Vaxart Obtains $12,500,000 Series B Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    600 Townsend St San Francisco, CA 94103
  • Company Description
    The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, biodefense vaccines, and second-generation versions of existing vaccines. The company is currently testing an avian flu vaccine.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funding will be used to advance the Company’s lead product, an oral vaccine for Avian influenza, through Phase I clinical trials.
  • M&A Terms
  • Venture Investor
    Care Capital
  • Venture Investor